In Waltham, Massachusetts, on May 13, 2026, Dyne Therapeutics, Inc. (Nasdaq: DYN), which specializes in developing treatments for individuals with genetically driven neuromuscular disorders, revealed plans for their involvement in upcoming investor conferences.